Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Analyst upgrades, led by Goldman Sachs Buy rating on Palantirs sovereign-AI and customized-software opportunities, are a key focus alongside the stocks breakout to new highs. Bulls celebrate the momentum and speculate about a short squeeze, while skeptics point to the stretched valuation and risk of a pullback.

Modernas Nasdaq-100 inclusion and expected index-fund buying, alongside a reported NIH push to accelerate cancer vaccines, are driving attention; traders also point to the companys Merck-partnered personalized melanoma vaccine. Bulls welcome the momentum and oncology prospects, while skeptics argue the rally may be driven by index flows and short covering and question whether the valuation can hold.

SpaceXs planned acquisition of low-band spectrum has intensified concerns that Starlink could become a stronger competitor to AST SpaceMobile, contributing to a sharp selloff. Traders are divided: bears see a threat to ASTSs business, while bulls argue its carrier-partner model and access to operators spectrum remain differentiators; CEO Abel Avellan pushed back on the competitive concerns.

NVAXs sharp rally is being linked to broader vaccine-sector strength after an NIH cancer-vaccine initiative lifted Moderna, while traders also focused on EU authorization of Sanofis Phase 3 COVID-flu combination trial and its potential milestone for Novavax. Many expect short-covering to amplify the move, but others question its durability and dismiss speculation about a Russian outbreak as unverified.

Microsofts launch of Microsoft-Decision-1, a specialized AI model for fast automated decisions, is drawing attention as shares push toward a record close. Traders are celebrating the breakout and AI momentum, while skeptics question whether the rally is justified and warn of an overextended valuation.

Hims & Hers shares surged as traders revisited the potential peptide opportunity, including speculation about regulatory access, alongside a broader rally in biotech and pharma names. Bulls viewed the move as a possible breakout or short-covering rally, while skeptics saw another short-lived pop in the stocks prolonged trading range.

Snowflakes stronger-than-expected quarterly results and raised outlook, with AI demand cited as boosting data-platform consumption, drove a sharp rally and continued focus on the stock. Traders are divided between expecting further gains and warning that the valuation is stretched, with some pointing to profit-taking after the earnings surge.

Mosaic is drawing attention after a steep selloff to multi-year lows, with traders pointing to weak results, high sulfur and other input costs, and phosphate production curtailments as pressure on margins. Some see fertilizer supply disruptions as a potential longer-term tailwind, but others question whether higher fertilizer prices can offset costs and weigh on farmer demand.

GameStops strong advance toward a 52-week high and breakout momentum are driving attention, with traders anticipating a possible short or options-driven squeeze. Excitement over potential gamma effects and rumored Ryan Cohen or Roaring Kitty developments is countered by skepticism that the rally lacks a confirmed catalyst and could fade or face dilution.

SpaceXs agreement to acquire Grain Managements 800 MHz spectrum portfolio has fueled fears that Starlink could become a direct wireless competitor, accompanying a sharp selloff in T-Mobile shares. Traders are divided between viewing the reaction as an overreaction given the infrastructure and capacity required to compete, and warning that SpaceX could pose a longer-term competitive threat.